Abstract

Background: COVID-19, which is a serious disease caused by the SARS-CoV-2, has affected several countries worldwide. Most people make a full recovery but others with severe symptoms have developed ARDS. During SARS-CoV-2 infection, abnormal amounts of inflammatory mediators indicate the severity of the illness. Recognizing aberrant coagulation findings early for coagulopathy is crucial and strongly advised to help COVID-19 patients, enhance their clinical results, and lessen serious illness ,enhance their clinical outcomes, and lessen serious consequences. Aim: our objective was to evaluate the levels of plasma inflammatory agents in SARS-COV-2 patients as a prognostic factor in disease severity in Egyptians. Patients and methods: in this study, 27 hospitalized individuals with COVID-19 confirmed diagnosis were divided into several categories; 5 mild cases, 8 moderate cases,10 severe cases, and 4 critically ill cases. Additionally, there were 5 enlisted health controls. We used the multiplex ELISA technique to assess 2 plasma inflammatory mediators in all subjects and compare disease severity. Results: patients with critically ill COVID-19 have much greater levels of C-reactive protein (CRP) and D-dimer than normal controls. Patients with critically ill COVID-19 severity and prognosis have higher CRP and D-dimer and showed a strong correlation (p<0.05) with the severity of the condition elucidating D -dimer functions as a marker for prognosis in COVID-19 patients. Conclusion: Present findings reveal that CRP and D-dimer levels are promising biomarkers for COVID-19 severity, that could be used as warning indicators of COVID-19 severity and aid in its prognosis and treatment.